Prospective research of Matrix Metalloproteinases (MMP) 2 and 9 as predictive biomarkers in metastatic kidney cancer patients treated with 2 anti angiogenic agents (Sunitinib or Pazopanib).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Patient male or female, aged of more than 18 years
2. Patient with any of the following conditions:
* Kidney cancer localized at diagnosis.
* Metastatic kidney cancer when anti-angiogenic therapy is initiated by Sunitinib or Pazopanib
* Oligometastatic kidney cancer without systemic treatment (local treatment)
3. ECOG = 0 to 2
4. Patient affiliated to, or beneficiary of, the national social security.
5. Patient having signed informed consent
Exclusion Criteria:
1. Patient previously treated with anti-angiogenic agents.
2. Person in an emergency situation, adult subject to a legal protection measure (a guardian, guardianship or safeguard of justice), or unable of expressing his / her consent.
3. Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons 4. History of malignant disease in the 5 years prior to inclusion (except basal cell carcinoma of the skin or epithelioma of the cervix in situ, or prostate cancer with a good prognosis (stage T \<3 and Gleason \<7)) accidentally discovered during the histological analysis of the tumor sample.
5- Pregnant or nursing women 6- Contraindications to the procedure of the study
Primary outcome measure(s)
Plasma level of the MMP2 and MMP9 markers — at initial sampling ELISA assay
Survival without progression — Up to 18 months date of progression (RECIST criteria), date of death
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
